Clinical trial
A Phase I/II Multicenter Study Combining Guadecitabine, a DNA Methyltransferase Inhibitor, With Atezolizumab, an Immune Checkpoint Inhibitor, in Patients With Intermediate or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
NCT02935361 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Multicenter Study Combining Guadecitabine, a DNA Methyltransferase Inhibitor, With Atezolizumab, an Immune Checkpoint Inhibitor, in Patients With Intermediate or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- Lead sponsor
- University of Southern California
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- November 2, 2016
- Completion date
- December 31, 2027
- Enrollment
- 33 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
chronic myelomonocytic leukemia, myelodysplastic syndrome, recurrent acute myeloid leukemia with myelodysplasia-related changes